血清CXCL12水平在预测颅脑损伤预后不良患者中的价值

Significance of serum CXCL12 level in predicting poor prognosis of patients with craniocerebral injury

摘要:

目的 探讨血清CXC趋化因子配体12（CXCL12）水平对颅脑损伤患者预后不良的预测价值。方法 回顾性分析124例颅脑损伤患者（A组）和86例健康体检者（B组）的资料，检测两组血清CXCL12水平。结果 A组与B组血清CXCL12水平比较及A组不同严重程度分型间比较，差异有统计学意义（P<0.05）。A组血清CXCL12高于B组，重型患者高于轻型和中型患者，中型患者高于轻型患者，A组不同严重分型间不良发生率及分型中不同预后间比较，差异有统计学意义（P<0.05）。A组预后不良发生率为20.97%，重型患者高于轻型和中型患者，且预后不良患者血清CXCL12高于预后良好患者，轻型、中型、重型中预后不良患者血清CXCL12水平均高于预后良好者。血清CXCL12水平预测A组预后不良的效能理想。结论 血清CXCL12水平可预测颅脑损伤患者的预后不良。

Abstract:

Objective To explore the predictive value of serum CXC chemokine ligand 12 (CXCL12) level for poor prognosis of patients with craniocerebral injury. Methods A retrospective analysis was performed on the data of 124 patients with craniocerebral injury and 86 subjects who underwent physical examinations, who were assigned to group A and group B, respectively. The serum CXCL12 level was determined. Results The serum CXCL12 level was significantly higher in group A than in group B, the serum CXCL12 level was significantly higher in patients with severe condition than in those with mild and moderate conditions, and the serum CXCL12 level was significantly higher in patients with moderate condition than in those with mild condition (P<0.05). The incidence of poor prognosis was 20.97% in group A, significantly higher in patients with severe condition than in those with mild and moderate conditions, the serum CXCL12 level was significantly higher in patients with poor prognosis than in those with good prognosis, with consistent results observed in the serum CXCL12 level between patients with poor prognosis (in mild, moderate, and severe conditions) and those with good prognosis(all P<0.05). The serum CXCL12 level had a satisfactory performance in predicting the poor prognosis in group A. Conclusions The serum CXCL12 level can predict the poor prognosis of patients with craniocerebral injury.